These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23305851)

  • 61. The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics.
    Beaulieu PL
    IDrugs; 2006 Jan; 9(1):39-43. PubMed ID: 16374732
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors.
    Das D; Hong J; Chen SH; Wang G; Beigelman L; Seiwert SD; Buckman BO
    Bioorg Med Chem; 2011 Aug; 19(16):4690-703. PubMed ID: 21798747
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells.
    Beaulieu PL; Bousquet Y; Gauthier J; Gillard J; Marquis M; McKercher G; Pellerin C; Valois S; Kukolj G
    J Med Chem; 2004 Dec; 47(27):6884-92. PubMed ID: 15615537
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.
    Chen YL; Tang J; Kesler MJ; Sham YY; Vince R; Geraghty RJ; Wang Z
    Bioorg Med Chem; 2012 Jan; 20(1):467-79. PubMed ID: 22100256
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A homogeneous, solid-phase assay for hepatitis C virus RNA-dependent RNA polymerase.
    Wang YK; Rigat KL; Roberts SB; Gao M
    Anal Biochem; 2006 Dec; 359(1):106-11. PubMed ID: 17054898
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
    Xue W; Jiao P; Liu H; Yao X
    Antiviral Res; 2014 Apr; 104():40-51. PubMed ID: 24462692
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.
    Jiang M; Zhang EZ; Ardzinski A; Tigges A; Davis A; Sullivan JC; Nelson M; Spanks J; Dorrian J; Nicolas O; Bartels DJ; Rao BG; Rijnbrand R; Kieffer TL
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5456-65. PubMed ID: 24982088
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Computational study on the drug resistance mechanism of HCV NS5B RNA-dependent RNA polymerase mutants V494I, V494A, M426A, and M423T to Filibuvir.
    Wang H; Guo C; Chen BZ; Ji M
    Antiviral Res; 2015 Jan; 113():79-92. PubMed ID: 25449363
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.
    Shih IH; Vliegen I; Peng B; Yang H; Hebner C; Paeshuyse J; Pürstinger G; Fenaux M; Tian Y; Mabery E; Qi X; Bahador G; Paulson M; Lehman LS; Bondy S; Tse W; Reiser H; Lee WA; Schmitz U; Neyts J; Zhong W
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4196-203. PubMed ID: 21746939
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
    Lin C; Kwong AD; Perni RB
    Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors.
    Kaushik-Basu N; Bopda-Waffo A; Talele TT; Basu A; Costa PR; da Silva AJ; Sarafianos SG; Noël F
    Nucleic Acids Res; 2008 Mar; 36(5):1482-96. PubMed ID: 18203743
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Synthesis and SAR optimization of diketo acid pharmacophore for HCV NS5B polymerase inhibition.
    Bhatt A; Gurukumar KR; Basu A; Patel MR; Kaushik-Basu N; Talele TT
    Eur J Med Chem; 2011 Oct; 46(10):5138-45. PubMed ID: 21893371
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.
    Court JJ; Poisson C; Ardzinski A; Bilimoria D; Chan L; Chandupatla K; Chauret N; Collier PN; Das SK; Denis F; Dorsch W; Iyer G; Lauffer D; L'Heureux L; Li P; Luisi BS; Mani N; Nanthakumar S; Nicolas O; Rao BG; Ronkin S; Selliah S; Shawgo RS; Tang Q; Waal ND; Yannopoulos CG; Green J
    J Med Chem; 2016 Jul; 59(13):6293-302. PubMed ID: 27366941
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Synthesis and antiviral properties of novel tetracyclic nucleoside inhibitors of hepatitis C NS5B polymerase.
    Di Francesco ME; Avolio S; Dessole G; Koch U; Pompei M; Pucci V; Rowley M; Summa V
    Nucleosides Nucleotides Nucleic Acids; 2012; 31(8):592-607. PubMed ID: 22908950
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate.
    McKercher G; Beaulieu PL; Lamarre D; LaPlante S; Lefebvre S; Pellerin C; Thauvette L; Kukolj G
    Nucleic Acids Res; 2004; 32(2):422-31. PubMed ID: 14739234
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.
    Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Preparation and biological evaluation of 1'-cyano-2'-C-methyl pyrimidine nucleosides as HCV NS5B polymerase inhibitors.
    Mish MR; Cho A; Kirschberg T; Xu J; Zonte CS; Fenaux M; Park Y; Babusis D; Feng JY; Ray AS; Kim CU
    Bioorg Med Chem Lett; 2014 Jul; 24(14):3092-5. PubMed ID: 24907145
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Distinct Characteristic Binding Modes of Benzofuran Core Inhibitors to Diverse Genotypes of Hepatitis C Virus NS5B Polymerase: A Molecular Simulation Study.
    Han D; Zhao F; Chen Y; Xue Y; Bao K; Chang Y; Lu J; Wang M; Liu T; Gao Q; Cui W; Xu Y
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125602
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Non-hydrolysable analogs of inorganic pyrophosphate as inhibitors of hepatitis C virus RNA-dependent RNA-polymerase].
    Ianvarev DV; Korovina AN; Usanov NN; Kochetkov SN
    Bioorg Khim; 2012; 38(2):257-62. PubMed ID: 22792731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.